Zuhayr Madhun, MD
Endocrinology · Beachwood, OHNPI 1891719415
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $963 of the $1,178 with a category attached, or 81.7%. It is spread thinly across 11 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $420, 4.5 times the $93 reported in 2020.
Across 39 payments — averaging $30.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$278
- Tandem Diabetes Care, Inc.$184
- Amgen$180
- Sequel Med Tech, LLC$163
- Dexcom, Inc.$139
- Sanofi$134
- plus $99 from 5 others
Across 1 payment — averaging $3595.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$4K
What the payments were for
- Consulting fees$17515%
- Food & beverage$96382%
- Education$403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $278 |
| Tandem Diabetes Care, Inc. | 9 | $184 |
| Amgen | 2 | $180 |
| Sequel Med Tech, LLC | 2 | $163 |
| Dexcom, Inc. | 4 | $139 |
| Sanofi | 1 | $134 |
| Pfizer | 1 | $29 |
| Medtronic | 1 | $23 |
| AstraZeneca | 1 | $20 |
| Insulet Corporation | 1 | $16 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$175
- TWIIST$150
- KEVZARA$134
- DEXCOM G7 GSS (161)$125
How this compares
Too few endocrinology providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $209,697 |
| TrulicityDulaglutide | 66 | $100,881 |
| JardianceEmpagliflozin | 65 | $68,823 |
| FarxigaDapagliflozin Propanediol | 33 | $46,444 |
| Humalog Kwikpen U-100Insulin Lispro | 146 | $40,959 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $36,583 |
| MounjaroTirzepatide | 27 | $35,748 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 231 | $33,068 |
| ProliaDenosumab | 18 | $31,125 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 42 | $26,046 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $25,614 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $21,394 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $21,263 |
| JanuviaSitagliptin Phosphate | 11 | $17,089 |
| HumalogInsulin Lispro | 46 | $12,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin N | $12 | $152,134152 claims |
| AstraZenecaFarxiga | $20 | $46,44433 claims |
| AmgenProlia | $180 | $31,12518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Ohioon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Beachwood
- Sunita MidhaAkron$422
- Rouba KortbawiCleveland$411
- Michael CanosCincinnati$0
- Hala MuallaDublin$0
- Stephen McDonaldMiamisburg$0
- Raheela KhawajaColumbus$0
- Dima DiabCincinnati$0
- Cristina OgrinCincinnati$0
- Benjamin O'DonnellColumbus$0
- Gary SchneiderColumbus$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.